CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

'Ticagrelor alone vs. dual antiplatelet therapy from 1 month after drug-eluting coronary stenting among patients with STEMI': a post hoc analysis of the randomized GLOBAL LEADERS trial Comprehensive Investigation of Circulating Biomarkers and their Causal Role in Atherosclerosis-related Risk Factors and Clinical Events 10-Year Outcomes of Stents Versus Coronary Artery Bypass Grafting for Left Main Coronary Artery Disease Sex-Based Outcomes in Patients With a High Bleeding Risk After Percutaneous Coronary Intervention and 1-Month Dual Antiplatelet Therapy: A Secondary Analysis of the LEADERS FREE Randomized Clinical Trial Impact of Percutaneous Revascularization on Exercise Hemodynamics in Patients With Stable Coronary Disease Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers The Science Underlying COVID-19: Implications for the Cardiovascular System Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial When, where, and how to target vascular inflammation in the post-CANTOS era?
|<<... 127 128 129 130 131 132 133 ...>>|

Review Article2018 Dec;7(2):127-149.

JOURNAL：Cardiol Ther. Article Link

Drug-Coated Balloon-Only Percutaneous Coronary Intervention for the Treatment of De Novo Coronary Artery Disease: A Systematic Review

Mohiaddin H, Wong TDFK, Burke-Gaffney A et al. Keywords: coronary artery disease; de novo; drug-coated balloon; drug-eluting balloon; percutaneous coronary intervention

FULL TEXT PDF

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top